Erectile dysfunction in patients with chronic pain treated with opioids

Area of Science:

• Urology
• Pain Management
• Endocrinology

Background:

• Chronic pain significantly impacts patient quality of life, often leading to comorbidities like sexual dysfunction.
• Opioid analgesics, while effective for pain, can cause erectile dysfunction (ED) by affecting the gonadal-pituitary-hypothalamic axis and testosterone levels.

Purpose of the Study:

• To evaluate the prevalence of ED in men with chronic pain treated long-term with opioids.
• To assess the effectiveness of andrological treatments for ED in this patient population.

Main Methods:

• A 3-year prospective observational study involving 105 patients reporting sexual dysfunction.
• Assessed pain intensity, erectile function (IIEF-EF), quality of life (EQ-VAS), sexual quality of life (MSLQ-QOL), anxiety/depression (HAD), and testosterone levels.
• A 6-month follow-up with standard andrological treatments (iPDE5 and/or testosterone gel) was conducted.

Main Results:

• ED was present in 27.6% of patients (mean age 57 years, mean morphine equivalent dose 107.1 mg/day).
• After 6 months of treatment, 42% of patients showed significant improvement in erectile function, with a 31% resolution rate (p=0.000).
• Improvements in erectile function correlated positively with enhanced sexual quality of life and reduced anxiety.

Conclusions:

• Andrological treatments significantly improve erectile function, sexual quality of life, and anxiety in chronic pain patients on long-term opioids.
• Routine assessment of sexual health history is recommended for pain management due to its significant impact on patients' emotional well-being and overall quality of life.
• Interdisciplinary treatment approaches demonstrate good clinical response for managing sexual dysfunction in this cohort.